SPHDF (Santhera Pharmaceuticals Holding AG) ROCE %: -8.99% (As of Dec. 2025)


SPHDF Santhera Pharmaceuticals Holding AG SPHDF
39 GF Score
Price $23.25
GF Value $24.73
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Santhera Pharmaceuticals Holding AG ROCE %?

Santhera Pharmaceuticals Holding AG SPHDF 39 ROCE % is -8.99% as of Dec. 2025. GuruFocus rates SPHDF with a GF Score™ of 39/100 and a GF Value™ of $24.73 (Fairly Valued). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Santhera Pharmaceuticals Holding AG's annualized ROCE % for the quarter that ended in Dec. 2025 was -8.99%.

Santhera Pharmaceuticals Holding AG  (OTCPK:SPHDF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Santhera Pharmaceuticals Holding AG ROCE % Related Terms

Santhera Pharmaceuticals Holding AG ROCE % Historical Data

* Premium members only.

The historical data trend for Santhera Pharmaceuticals Holding AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Santhera Pharmaceuticals Holding AG ROCE % Chart

Santhera Pharmaceuticals Holding AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -63.75 -137.55 197.44 -39.37 -41.44

Santhera Pharmaceuticals Holding AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 730.87 -36.50 -56.57 -79.91 -8.99
SPHDF
39GF Score
Santhera Pharmaceuticals Holding AG SPHDF
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Santhera Pharmaceuticals Holding AG ROCE % Calculation

Santhera Pharmaceuticals Holding AG's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-47.051/( ( (171.027 - 51.753) + (185.826 - 78.016) )/ 2 )
=-47.051/( (119.274+107.81)/ 2 )
=-47.051/113.542
=-41.44 %

Santhera Pharmaceuticals Holding AG's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-8.88/( ( (160.807 - 71.054) + (185.826 - 78.016) )/ 2 )
=-8.88/( ( 89.753 + 107.81 )/ 2 )
=-8.88/98.7815
=-8.99 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -8.99% mean?
Santhera Pharmaceuticals Holding AG (SPHDF) has a ROCE % of -8.99% as of Dec. 2025.
Is Santhera Pharmaceuticals Holding AG's ROCE % too high?
Santhera Pharmaceuticals Holding AG's current ROCE % is -8.99%. Overall, Santhera Pharmaceuticals Holding AG has a GF Score™ of 39/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Santhera Pharmaceuticals Holding AG's ROCE % compare to VRTX and REGN?
Santhera Pharmaceuticals Holding AG's ROCE % of -8.99% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Santhera Pharmaceuticals Holding AG's current ROCE % is -8.99%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santhera Pharmaceuticals Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG (SPHDF) is currently considered Fairly Valued. The stock's GF Value™ is $24.73, compared to a current price of $23.25 — trading 6% below its estimated fair value. The current ROCE % is -8.99%. Santhera Pharmaceuticals Holding AG's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Santhera Pharmaceuticals Holding AG (SPHDF), the current ROCE % is -8.99% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Santhera Pharmaceuticals Holding AG (SPHDF) Overvalued in 2026?

Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG stock appears to be undervalued. The current stock price of $23.25 is trading 6% below its estimated GF Value™ of $24.73. GuruFocus considers Santhera Pharmaceuticals Holding AG to be Fairly Valued.

Key valuation signals for SPHDF:

  • ROCE %: -8.99%
  • GF Value™: $24.73 vs. price of $23.25 (6% below fair value)
  • GF Score™: 39/100 with 7 warning signs

No single metric tells the full story. See the SPHDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Santhera Pharmaceuticals Holding AG Business Description

Address Hohenrainstrasse 24, Pratteln, CHE, 4133
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company committed to developing and commercializing medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs. It is focused on the development of treatments for pulmonary and neuromuscular diseases that currently lack treatment options. The company is currently engaged in the rollout of its AGAMREE (vamorolone) medicine for the treatment of Duchenne muscular dystrophy (DMD) globally. Santhera has one operating segment, namely the development and commercialization of products for the treatment of neuromuscular diseases. Geographically, the company generates maximum revenue from Europe, and the rest from Asia and North America.
39GF Score

Get the complete analysis for SPHDF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.25
Price
$24.73
GF Value